BeyondSpring highlights confirmatory Phase 3 DUBLIN-4 trial plan for plinabulin in post-ICI NSCLC

• BeyondSpring investor presentation highlighted plinabulin as a late-stage oncology asset targeting post-ICI, driver-negative non-squamous NSCLC.
• DUBLIN-4 confirmatory Phase 3 planned for 442 patients; double-blind docetaxel-plinabulin versus docetaxel; overall survival primary endpoint.
• Interim analysis targeted for 2H 2028; potential launch projected for 2030/31.
• DUBLIN-3 Phase 3 met overall survival endpoint; OS HR 0.82; p=0.0399 in EGFR wild-type 2L/3L NSCLC.
• Non-squamous subgroup showed median OS 11.37 vs 8.81 months; HR 0.72; p=0.0078; grade 4 neutropenia 5.13% vs 33.58%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeyondSpring Inc. published the original content used to generate this news brief on September 01, 2026, and is solely responsible for the information contained therein.